Lisa Wissler
Research Subjects
Lisa Wissler has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anders Gunnarsson
AstraZeneca (Sweden)
1 shared publication - Anders Hogner
AstraZeneca
1 shared publication - Andrey I. Frolov
Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
1 shared publication - Anna Aagaard
Structure and BioPhysics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
1 shared publication - Arjan Snijder
Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
1 shared publication - Carol MacKintosh
School of Life Sciences, University of Dundee, UK
1 shared publication
Latest Publications
- Open Access
- 8 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (25) , 7057-7067
Combining structural and coevolution information to unveil allosteric sites
Structure-based three-parameter model that integrates local binding site information, coevolutionary information, and information on dynamic allostery to identify potentially hidden allosteric sites in ensembles of protein structures.
- 8 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (25) , 7057-7067
Open AccessCombining structural and coevolution information to unveil allosteric sites
Structure-based three-parameter model that integrates local binding site information, coevolutionary information, and information on dynamic allostery to identify potentially hidden allosteric sites in ensembles of protein structures.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100551
Glucocorticoid receptor Thr524 phosphorylation by MINK1 induces interactions with 14-3-3 protein regulators
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100551
Open AccessGlucocorticoid receptor Thr524 phosphorylation by MINK1 induces interactions with 14-3-3 protein regulators
- Open Access
- 2 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Molecular tuning of farnesoid X receptor partial agonism
The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.
- 2 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Open AccessMolecular tuning of farnesoid X receptor partial agonism
The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.